The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
L ong-acting inject ables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophrenia ...
Hosted on MSN
Restoring intimacy: Navigating sexual dysfunction in schizophrenia and your treatment options
If schizophrenia is impacting your sex life, youre far from alone. Research suggests that more than half of people with schizophrenia experience some type of sexual issue, which can include erectile ...
Researchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, Technology and Research (A*STAR) have made strides in understanding the ...
Cobenfy (xanomeline-trospium chloride) was approved for the treatment of adults with schizophrenia in 2024. Cobenfy is the first medicine approved for the treatment of schizophrenia that works ...
The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...
Everyday Health on MSN
Psychosis vs. schizophrenia: What’s the difference?
Psychosis is often short-term, whereas schizophrenia is a lifelong condition. Learn more about this and other differences between the two.
I remember the first time I heard the time "treatment resistant." It was from a friend as they shared with me their mental health story. As this conversation took place some years before my schooling ...
Schizophrenia is a complex medical condition that may require switching from an oral option or between different long-acting injectable options during the patient treatment journey. These data further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results